Citation:Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, et al 2014

Citation

Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014 Jun 20;32(18):1902-8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24841974.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, et al 2014	What is the optimal third-line therapy in unselected patients with stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, et al 2014 2	What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the optimal third-line therapy in unselected patients with stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)

Cited by

1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
2. What is the optimal third-line therapy in unselected patients with stage IV inoperable NSCLC?